Cargando…

Rapid increases in epinephrine concentration following presumed intra–blood vessel administration via epinephrine autoinjector

While epinephrine autoinjectors have been the standard of care for the out-of-hospital treatment of anaphylaxis, their use has been associated with potential cardiovascular risks including intravascular injection, resulting in rapid increases in blood pressure and pulse rate. ARS Pharmaceuticals, In...

Descripción completa

Detalles Bibliográficos
Autores principales: Ebisawa, Motohiro, Kaliner, Michael A., Lowenthal, Richard, Tanimoto, Sarina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10509835/
https://www.ncbi.nlm.nih.gov/pubmed/37779532
http://dx.doi.org/10.1016/j.jacig.2023.100118
_version_ 1785107840471400448
author Ebisawa, Motohiro
Kaliner, Michael A.
Lowenthal, Richard
Tanimoto, Sarina
author_facet Ebisawa, Motohiro
Kaliner, Michael A.
Lowenthal, Richard
Tanimoto, Sarina
author_sort Ebisawa, Motohiro
collection PubMed
description While epinephrine autoinjectors have been the standard of care for the out-of-hospital treatment of anaphylaxis, their use has been associated with potential cardiovascular risks including intravascular injection, resulting in rapid increases in blood pressure and pulse rate. ARS Pharmaceuticals, Inc conducted a clinical trial designed to assess the pharmacokinetics and pharmacodynamics of ARS-1, an intranasal epinephrine spray in development, compared to EpiPen in subjects with a documented history of seasonal allergies. During the conduct of this study, a presumed intrablood vessel injection following EpiPen administration by a medical professional was observed in a female subject. The subject reported palpitations within 1 minute of receiving EpiPen injection; at 4 minutes postinjection, blood pressure was 221/128 mmHg (baseline 118/79), and pulse rate was 71 (baseline 56). In contrast, across all subjects (N = 36) the mean maximum increases in systolic blood pressure, diastolic blood pressure, and pulse rate were 12.0 mmHg, 2.8 mmHg, and 16.3 bpm, respectively. When this subject was removed from the pharmacokinetic analysis, the mean epinephrine C(max) of the remaining subjects was 801.1 pg/mL after administration of EpiPen; however, at 4 minutes postinjection this subject had a plasma epinephrine level of 4390 pg/mL, a >6.3-fold increase, illustrating the risks that may be associated with out-of-hospital epinephrine injections that are included as warnings in the product labeling. Despite the potential risks associated with accidental intravessel injection, it is important to note that intramuscular administration of epinephrine is currently the best currently available out-of-hospital treatment for severe allergic reactions and anaphylaxis.
format Online
Article
Text
id pubmed-10509835
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-105098352023-09-29 Rapid increases in epinephrine concentration following presumed intra–blood vessel administration via epinephrine autoinjector Ebisawa, Motohiro Kaliner, Michael A. Lowenthal, Richard Tanimoto, Sarina J Allergy Clin Immunol Glob Case Report While epinephrine autoinjectors have been the standard of care for the out-of-hospital treatment of anaphylaxis, their use has been associated with potential cardiovascular risks including intravascular injection, resulting in rapid increases in blood pressure and pulse rate. ARS Pharmaceuticals, Inc conducted a clinical trial designed to assess the pharmacokinetics and pharmacodynamics of ARS-1, an intranasal epinephrine spray in development, compared to EpiPen in subjects with a documented history of seasonal allergies. During the conduct of this study, a presumed intrablood vessel injection following EpiPen administration by a medical professional was observed in a female subject. The subject reported palpitations within 1 minute of receiving EpiPen injection; at 4 minutes postinjection, blood pressure was 221/128 mmHg (baseline 118/79), and pulse rate was 71 (baseline 56). In contrast, across all subjects (N = 36) the mean maximum increases in systolic blood pressure, diastolic blood pressure, and pulse rate were 12.0 mmHg, 2.8 mmHg, and 16.3 bpm, respectively. When this subject was removed from the pharmacokinetic analysis, the mean epinephrine C(max) of the remaining subjects was 801.1 pg/mL after administration of EpiPen; however, at 4 minutes postinjection this subject had a plasma epinephrine level of 4390 pg/mL, a >6.3-fold increase, illustrating the risks that may be associated with out-of-hospital epinephrine injections that are included as warnings in the product labeling. Despite the potential risks associated with accidental intravessel injection, it is important to note that intramuscular administration of epinephrine is currently the best currently available out-of-hospital treatment for severe allergic reactions and anaphylaxis. Elsevier 2023-05-23 /pmc/articles/PMC10509835/ /pubmed/37779532 http://dx.doi.org/10.1016/j.jacig.2023.100118 Text en © 2023 The Author(s) https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Case Report
Ebisawa, Motohiro
Kaliner, Michael A.
Lowenthal, Richard
Tanimoto, Sarina
Rapid increases in epinephrine concentration following presumed intra–blood vessel administration via epinephrine autoinjector
title Rapid increases in epinephrine concentration following presumed intra–blood vessel administration via epinephrine autoinjector
title_full Rapid increases in epinephrine concentration following presumed intra–blood vessel administration via epinephrine autoinjector
title_fullStr Rapid increases in epinephrine concentration following presumed intra–blood vessel administration via epinephrine autoinjector
title_full_unstemmed Rapid increases in epinephrine concentration following presumed intra–blood vessel administration via epinephrine autoinjector
title_short Rapid increases in epinephrine concentration following presumed intra–blood vessel administration via epinephrine autoinjector
title_sort rapid increases in epinephrine concentration following presumed intra–blood vessel administration via epinephrine autoinjector
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10509835/
https://www.ncbi.nlm.nih.gov/pubmed/37779532
http://dx.doi.org/10.1016/j.jacig.2023.100118
work_keys_str_mv AT ebisawamotohiro rapidincreasesinepinephrineconcentrationfollowingpresumedintrabloodvesseladministrationviaepinephrineautoinjector
AT kalinermichaela rapidincreasesinepinephrineconcentrationfollowingpresumedintrabloodvesseladministrationviaepinephrineautoinjector
AT lowenthalrichard rapidincreasesinepinephrineconcentrationfollowingpresumedintrabloodvesseladministrationviaepinephrineautoinjector
AT tanimotosarina rapidincreasesinepinephrineconcentrationfollowingpresumedintrabloodvesseladministrationviaepinephrineautoinjector